Literature DB >> 26658888

Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.

Aurélie Mbeutcha1,2, Ilaria Lucca1,3, Vitaly Margulis4, Jose A Karam5, Christopher G Wood5, Michela de Martino1, Romain Mathieu1,6, Andrea Haitel7, Evanguelos Xylinas8, Luis Kluth9, Morgan Rouprêt10, Pierre I Karakiewicz11, Alberto Briganti12, Michael Rink9, Malte Rieken1,13, Alon Z Weizer14, Jay D Raman15, Nathalie Rioux-Leclecq16, Christian Bolenz17, Karim Bensalah6, Yair Lotan4, Christian Seitz1, Mesut Remzi18, Shahrokh F Shariat19,20,21, Tobias Klatte1.   

Abstract

BACKGROUND: Excision repair cross-complementing 1 (ERCC1) has been associated with outcomes of urothelial carcinoma of the bladder, but was not yet studied in upper tract urothelial carcinoma (UTUC). The aim of this study was to assess the prognostic role of ERCC1 expression in a large international cohort of UTUC patients.
METHODS: Immunohistochemical ERCC1 expression was evaluated in 716 UTUC patients who underwent radical nephroureterectomy with curative intent. ERCC1 was considered positive when the H-score was >1.0. Associations with overall survival and cancer-specific survival were assessed using univariable and multivariable Cox models.
RESULTS: ERCC1 was expressed in 303 tumors (42.3 %) and linked with the presence of tumor necrosis (16.2 vs. 10.4 %, p = 0.023), but not with any other clinical or pathological variable. ERCC1 status did not predict cancer-specific survival and overall survival on both univariable (p = 0.70 and 0.32, respectively) and multivariable analyses (p = 0.48 and 0.33, respectively).
CONCLUSIONS: ERCC1 is expressed in a significant proportion of UTUC and is linked with tumor necrosis, but its expression appears not to be associated with prognosis following radical nephroureterectomy.

Entities:  

Keywords:  Adjuvant; Cisplatin; ERCC1; Prediction; Prognosis; Survival; Upper tract; Urothelial

Mesh:

Substances:

Year:  2015        PMID: 26658888     DOI: 10.1007/s00345-015-1737-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

1.  Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Authors:  J Bellmunt; L Paz-Ares; M Cuello; F L Cecere; S Albiol; V Guillem; E Gallardo; J Carles; P Mendez; J J de la Cruz; M Taron; R Rosell; J Baselga
Journal:  Ann Oncol       Date:  2007-01-17       Impact factor: 32.976

Review 2.  How nucleotide excision repair protects against cancer.

Authors:  E C Friedberg
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy.

Authors:  Tobias Klatte; Evanguelos Xylinas; Malte Rieken; Morgan Rouprêt; Harun Fajkovic; Christian Seitz; Pierre I Karakiewicz; Yair Lotan; Marko Babjuk; Michela de Martino; Shahrokh F Shariat
Journal:  Urol Oncol       Date:  2014-02-02       Impact factor: 3.498

Review 4.  Urothelial carcinoma of the bladder and the upper tract: disparate twins.

Authors:  David A Green; Michael Rink; Evanguelos Xylinas; Surena F Matin; Arnulf Stenzl; Morgan Roupret; Pierre I Karakiewicz; Douglas S Scherr; Shahrokh F Shariat
Journal:  J Urol       Date:  2012-09-27       Impact factor: 7.450

5.  European guidelines on upper tract urothelial carcinomas: 2013 update.

Authors:  Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard Sylvester; Max Burger; Nigel Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-03-19       Impact factor: 20.096

6.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

7.  Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.

Authors:  Francesca Mazzoni; Fabiana Letizia Cecere; Giulia Meoni; Costanza Giuliani; Luca Boni; Andrea Camerini; Sara Lucchesi; Francesca Martella; Domenico Amoroso; Elisa Lucherini; Francesca Torricelli; Francesco Di Costanzo
Journal:  Lung Cancer       Date:  2013-09-03       Impact factor: 5.705

Review 8.  Challenges of cancer biomarker profiling.

Authors:  Karim Bensalah; Francesco Montorsi; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2007-10-01       Impact factor: 20.096

9.  The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study.

Authors:  Ilaria Lucca; Wassim Kassouf; Anil Kapoor; Adrian Fairey; Ricardo A Rendon; Jonathan I Izawa; Peter C Black; Harun Fajkovic; Christian Seitz; Mesut Remzi; Peter Nyirády; Morgan Rouprêt; Vitaly Margulis; Yair Lotan; Michela de Martino; Sebastian L Hofbauer; Pierre I Karakiewicz; Alberto Briganti; Giacomo Novara; Shahrokh F Shariat; Tobias Klatte
Journal:  BJU Int       Date:  2015-03-06       Impact factor: 5.588

10.  External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.

Authors:  J H Ku; K C Moon; J H Jung; S H Jeong; C Kwak; H H Kim
Journal:  Br J Cancer       Date:  2013-08-15       Impact factor: 7.640

View more
  4 in total

Review 1.  Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.

Authors:  Ganeshkumar Rajendran; John A Taylor; Benjamin L Woolbright
Journal:  Cancer Drug Resist       Date:  2021-03-19

2.  Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.

Authors:  Wen Liu; Lijiang Sun; Fengju Guan; Fangming Wang; Guiming Zhang
Journal:  Dis Markers       Date:  2019-09-03       Impact factor: 3.434

Review 3.  Clinical Perspectives of ERCC1 in Bladder Cancer.

Authors:  Konstantinos Koutsoukos; Angeliki Andrikopoulou; Nikos Dedes; Flora Zagouri; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

4.  Is ERCC1 a prognostic biomarker for urothelial cancer following radical cystectomy? A long-term analysis.

Authors:  Mateusz Obarzanowski; Janusz Kopczynski; Jaroslaw Jaskulski; Antoni Domagala; Pawel Macek; Stanislaw Gozdz; Maciej Salagierski
Journal:  Cent European J Urol       Date:  2021-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.